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ABSTRACT: 
Rabies is a fatal encephalitis transmitted to humans by the bite of 
rabid animals. Which is the most common mode of transmission in our 
country. Right now the important focus is on the post exposure 
prophylaxis since no effective treatment options are available till date. 
Over the course of time post exposure prophylaxis has been changing 
mainly because of the production of more potent vaccines and better 
understanding in the field of immune response for vaccination against 
rabies. 
          In our study we try to find out the effectiveness between the third 
and fourth dose of anti-rabies vaccination used in post exposure 
prophylaxis when given via intramuscular route. RAPID 
FLOURESCENT FOCUS INHIBITION TEST was used to measure the 
level of antibodies after seven days of each corresponding doses of 
vaccination. If the adequate levels of antibodies were reached after the 
third dose and also if no significant increase in antibody titer after the 
fourth dose, the need for the fourth dose in the schedule can be 
eliminated. 
        In our study we also try to assess the knowledge, attitude and 
practice regarding dog bite among the patients coming for post exposure 
prophylaxis. 
 Conclusion: 
In our study we found that the adequate levels of antibodies are reached 
even after the third dose itself, but the increase in antibody titer was 
highly significant when compared to the third dose. Therefore fourth 
dose has to be given as per the recommended schedule. 
In our study we found that the knowledge levels regarding dog bites and 
rabies are adequate but the attitude and practices are not adequate and 
needs to be improved. 
Keywords: 
Dog bite, rabies, post exposure prophylaxis, intradermal route, 
intramuscular route, antibody titers, rapid fluorescent focus inhibition, 
knowledge, attitude, practices. 
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INTRODUCTION 
 
Rabies is a fatal encephalitis caused by rabies virus. It is acquired 
through the bite of rabid animal as well as via contamination of mucus 
membrane with saliva of rabid animal. The other modes of transmission of 
rabies virus do not play a predominant role in the rabies transmission in our 
country. 
 
Once diagnosed rabies is nearly always fatal. Because till today there 
was no effective management exist for human rabies. Mortality is always 
nearly 100%. Even in very rare cases of recovery, severe neurological 
sequalae persist. This calls for the effective post exposure management 
prevention of rabies. 
 
           When the post exposure prophylaxis is properly administered the 
rabies is completely preventable. Post exposure prophylaxis consist of wound 
management, active immunization against rabies and passive immunization 
in the form of human or equine immunoglobulin if needed. 
 
           Current guidelines are recommended by both world health 
organization and center for disease control. Post exposure prophylaxis by 
means of active immunization is given via intramuscular or intradermal route. 
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Till 2010 both regimen has a total duration of 28 days. Center for disease 
control in June 2010 came up with the recommendation of reduced dose of 
post exposure intra muscular active immunization. There by reducing the 
duration of active immunization for post exposure prophylaxis has been 
reduced to 14 days. This improves the patient compliance when compared to 
28 days  
 
           In India   both intramuscular and intradermal route was approved for 
use.  But intradermal route is widely followed in government run institutions 
because of the economic concerns. The intradermal route requires less 
vaccine dose. The patient’s compliance is decreased when the number of 
days required for completion of active immunization. 
. 
          Recently many studies demonstrate that neutralizing antibody levels 
against rabies virus reaches above the protective levels required after 4th 
intramuscular dose. The test used for this measurement is Rapid Fluorescent 
Focus Inhibition Test [RFFIT], which is the authorized for this purpose by 
world health organization. Now studies are coming up with results showing 
that even after the 3rd intramuscular dose the protective antibody levels are 
attained and these are maintained during follow up also. These leads to the 
reduced vaccine recommendation by center for disease control.  Even though 
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the vaccination dose has been changing over time, the dose of anti-rabies 
immunoglobulin required for passive immunization remains unchanged. 
 
In our study we try to assess the antibody response between the 3rd and 
4th dose of intramuscular anti-rabies vaccination. So unless significant titer 
increase is noted after the fourth dose, the need for the fourth dose can be 
eliminated. We also try to assess the knowledge attitude and practice 
regarding dog bite in the dog bitten individuals. 
 
  
  
 
 
 
AIM AND OBJECTIVES 
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AIM AND OBJECTIVES 
 
 To study the effectiveness of third dose of ARV with fourth IM dose to 
determine whether the fourth dose is really needed or not? 
 
 
 To assess the knowledge attitude and practice among patients receiving 
post exposure prophylaxis 
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REVIEW OF LITERATURE 
 
ETYMOLOGY: 
The term rabies means “MADNESS” in Latin .it can also be related to 
Sanskrit word “RABHAS” means “TO DO VIOLENCE”. While the Greek 
word “LYSSA” means “VIOLENT” this forms the basis of the genus name 
Lyssavirus. 
 
HISTORICAL SIGNIFICANCE: 
Rabies has been known to mankind since around 2000 B.C. the first 
written evidences can be found in Mesopotamian Code of Eshnuna 1930 B.C. 
one of the earlier methods of treatment consists of wound cauterization by 
applying heated “St Hubert’s key” 
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RABIES VIRUS: 
Family :  Rhabdiviridae 
Order  :   Mononeglavirus 
Genus :  Lyssavirus 
 
The rabies virus is bullet-shaped, the dimension of the viruses are 
around 180 nm in length and around 75 nm in diameter. The virus contains a 
helical nucleocapsid of 30–35coils with a length unwound between 4.2 and 
4.6µm. The nucleocapsid enclosed in a 7.5–10-nm-thick lipoprotein 
envelope; from this envelope, glycoprotein (G protein) spikes project out 
another 10 nm. Except the blunt end these glycoprotein covers the entire 
surface of viruses. The viral genome is a single negative strand of RNA 
weighing 4.6 MDa, and contains a sequence of 11932 nucleotides. This 
RNAencodes five genes, named N, NS (or M1), M (or M), G, and L. The 
Nnucleoprotein binds to the RNA and is probably involved in the control of 
viral RNA replication; it is a potential immunogen. The purpose of the NS 
phosphoprotein is less clear, but it may control the L protein, which is the 
polymerase for replication. The M (matrix) protein is the major structural 
protein and is probably located between the nucleocapsid and lipoprotein 
envelope; its role is uncertain. The G protein is involved in cell surface 
reception, and it is the only antigen that induces virus-neutralizing antibodies. 
Variability in this protein accounts for serotypic differences among 
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lyssaviruses, and mutations at arginine 333cause loss of virulence 
(substitution with glutamine or isoleucine). This arginine residue is required 
for G protein mediated fusion of the viral envelope with neurons. Molecular 
modifications of the G protein can increase its antigenicity and may aid in the 
search for better vaccines. 
The nicotinic acetylcholine receptor is an important viral binding site, 
but it is probably not the only one. Once bound to the receptor, receptor 
mediated endocytosis allows the virus to enter the neuron. This forms a 
coated pit, which then fuses with a lysosome, where enzymes release the 
nucleocapsid into the cytosol. Five messenger RNAs (mRNAs) for 
production of the viral proteins are transcribed, and a full-length, positively 
stranded RNA is produced as the template for the viral progeny. The 
envelope forms from host cisternal membranes into which the G and M 
proteins are inserted. In natural infections the virus accumulates in 
cytoplasmic cisterns from which it is released either by membrane fusion or 
dissolution of the cell. 
 
VIRUS SUSCEPTIBILITY: 
Rabies virus does not with stand heat. The viruses will be having the 
half-life of about less than one minute at 560C when compared to several 
hours at 370C. At 4°C, there is little loss after 2 weeks. The lipid coat is 
disrupted by detergents or a 1% soap solution. Other virucidal agents include 
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iodine solutions (1:10000 available iodine), 45% ethanol and 1% 
benzalkonium chloride, but phenol is not so effective. 
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ELECTRON MICROSCOPE VIEW OF CLUMPS OF RABIES VIRUS: 
 
COMPONENTS OF RABIES VIRUS: 
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RABIES VIRAL GENOME AND ITS FUNCTION: 
 
 
EPIDEMOLOGY: 
Rabies is a viral zoonos is causing almost uniformly fatal encephalitis 
in humans and other mammals. Human rabies is one of the most under 
reported diseases worldwide. Rabies is enzootic worldwide. The terrestrial 
mammals are free of rabies in Western Europe and Australia but rabies-
related lyssa viruses are found to be present in bats. 
          Important reservoirs are domestic dogs, jackals, mongoose, bats, 
skunks, raccoons, coyote, and wolves. In India dogs, wolves, jackals forms 
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the important link. Rabies related deaths are high in India, Bangladesh, 
Pakistan, and Thailand. 
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TRANSMISSSION OF INFECTION: 
 ANIMAL CONTACT: 
                 Humans get infected by virus laden saliva, inoculated during bite 
of rabid animal into a wound or on to a mucous membrane may result in 
infection. Intact skin serves as a barrier for viral entry. 
 
HUMAN CONTACT: 
There are some anecdotal reports of transmission of infection via 
contact with human saliva, kissing, biting, sexual intercourse, breast feeding, 
and eating infected meat but they are largely unproven and viraemia in blood 
has not been detected 
In contrast to events in neurons, virus replication in acinar cells of the 
salivary glands produces large amounts of extracellular virus. Although there 
is no evidence of viraemia, rabies virus is shed in human lachrymal and 
respiratory tract secretions and possibly in urine and in milk. 
Transmission has occurred through grafting of infected corneas. Six 
virologically proven cases followed transplants from donors with 
unsuspected rabies. In Texas and in Germany, mysterious encephalitis killed 
a total of seven organ transplant recipients. The documented evidence 
regarding rabies viral transmission via transplantation exist for 
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1 .Liver 
2. Kidney 
3.Pancreas 
4. Iliac artery grafts 
 
The above said grafts have been harvested from two young donors died 
of undiagnosed neurological disease. Later through history and background 
check revealed a previous bat bite in USA and contact with a dog in India. 
Two cornea transplant recipients were given rabies post-exposure 
prophylaxis and remain healthy. 
 
Transplacental infection occurs in animals, and a Turkish woman and 
her 2-day-old infant died of virologically confirmed rabies. This is 
exceptional. Many mothers with rabies have been delivered of healthy babies. 
       Two rabies infections resulted from inhaled aerosols of ‘fixed’ Virus in 
laboratory accidents. Two more people were possibly infected by inhalation 
of aerosolized virus in bat-infested caves, but direct bat contact was not 
excluded. Butchering dogs or cats is another source of rabies, but consuming 
the cooked rabid meat did not cause infection. 
15 
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PATHOGENESIS: 
 
        After virus inoculation into the wound or contact with mucous 
membrane it replicates in the muscle cells by doing so it infects the muscle 
spindles, via the muscle spindle it then infects the nerve that innervates the 
muscle spindle then it moves centripetally in the axons of the infected nerve 
via fast axon transport. The virus is first seen in the dorsal root ganglion 
before spinal cord which confirms the transport of rabies virus via sensory 
nerves. 
 
          Some studies suggest the neuromuscular junction plays a major role in 
neuronal invasion because there is a partial sequence homology exists 
between snake neurotoxins and rabies viral glycoprotein that plays an 
important role in adhesion. There is also evidence that by blocking 
acetylcholine receptors viral attachment can be inhibited. However, rabies 
virus can enter neurons that do not express acetylcholine receptors but with 
less efficacy therefore other receptors must exists for viral attachment 
 
         Natural course of infection consists of local viral replication before 
central nervous system infection, this is perhaps to increase the inoculum 
before nervous system infection. Thus timely administration of rabies 
immunoglobulin and active immunization can prevent the infection in to 
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nervous system and thus the disease. Once the virus gains the entry into 
nervous system the current therapeutic measures available won’t be much 
helpful. 
 
 After reaching spinal cord it spreads to entire central nervous system 
via synaptic connectivity. From the central nervous system it spreads to the 
entire body via peripheral nerves. 
 
Mechanism of rabies viral damage to central nervous system remains 
obscure because the neuronal necrosis is very minimal or either absent. The 
virus may interfere with neurotransmission. There is also evidence suggestion 
excitotoxic mechanism by increasing nitric oxide levels up to 30 fold 
increase. The rabies virus infection also capable of inducing apoptosis in in T 
lymphocytes this may form the basis of failure of immune system to clear the 
virus. 
18 
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PATHOLOGY: 
 
               Gross brain specimen of rabies encephalitis mainly consist of 
cerebral congestion and few petechial hemorrhages. Microscopically 
lymphocytic perivenous infiltrate can be observed. There may be focal areas 
of demyelination which may mimic Guillian Barre syndrome like 
polyneuropathy. There may be perineural infiltration called Babes nodules 
can be present. 
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The pathognomic finding of Negri bodies is found only in 75% of 
cases. They are found in hippocampus, purkinje cells of cerebellum and in 
medulla .the involvement of hippocampus explains about the aggressive 
behavior of the infected persons and animal. These above said findings are 
present mainly in furious rabies 
 
 
Negri bodies are oval eosinophilic cytoplasmic inclusion bodies 
ranging from 1– 7 micrometers. They mainly consist of viral nucleocapsids. 
Lyssa bodies are structurally similar to Negri bodies. They are also isolated 
from heart. Involvement of heart resembles myocarditis in 
hypercatecholamines states like pheochromocytoma, sub arachnoid 
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hemorrhage and tetanus. Adelchi Negri first thought that Negri bodies are 
protozoan organisms and named it as Neurocytes hydrophobiae. 
 
           Paralytic rabies mainly affects spinal cord with necrosis and severe 
inflammation. Brain stem is involved to lesser extent in paralytic or dumb 
rabies. 
 
IMMUNE RESPONSE: 
 
The natural immune response to rabies virus infection is insufficient to 
prevent the development of disease which once developed is invariably fatal. 
Rabies viral infection can produce immunosuppression by inducing apoptosis 
of T lymphocytes. Antibodies levels that can be measured can develop late in 
the course of the disease by the time it is too late. Those who develop cellular 
immunity to develop furious rabies and die faster than those who don’t have 
such a response these are the patients who develop paralytic rabies. 
Immunosuppression by rabies can also be explained by the production of 
interleukin 1 in the central nervous system. There is one theory that rabies 
virus persist inside macrophages and emerge later to cause the disease. This 
may be explain the very long incubation seen in some cases. 
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CLINICAL MANIFESTATIONS OF HUMAN RABIES: 
 
The variables affecting the development of disease following exposure 
depends upon 
1. Viral inoculum – the chances of are viral inoculum is more when the 
rabid animal bites the exposed rather than the areas covered by means 
of clothes. Because clothes may remove the saliva at the time of bite. 
2. Probability increases with multiple bite wound rather than single, but 
not always. 
3. Location of bite site [proximity to brain] – bites on faces are more 
likely to cause disease than those on the extremities. 
 
Incubation period: varies from few days to 90 days 
 
There is evidence that rabies encephalitis can present after an incubation 
period of 25 years 
 
CLASSIFICATION: 
Based on the clinical manifestations rabies is classified into  
            1. Furious or encephalitic rabies 
                     2. Dumb or paralytic rabies 
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           In the prodromal phase it could not be differentiated from other viral 
illness based on the symptoms only. The furious form presents with 
hydrophobia, aerophobia, delirium and agitation. The paralytic form can 
present as an ascending paralysis. In either the case course usually last for 2 
to 14 days before the coma supervenes. Once the coma settles in death 
usually occurs in 1 to 2 weeks. Cardiac arrhythmias mainly supraventricular 
can occur which may be due to brainstem dysfunction or can be due to 
myocarditis. Autonomic disturbances also seen like piloerection, marked 
salivation, anisocoria and rarely priapism and spontaneous ejaculation. 
Weakness is the main presentation in paralytic type which can more in the 
extremity where the viruses are introduced. 
 
Myoedema is present during the prodromal phase and it persists 
throughout the disease.  
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DIAGNOSIS: 
 
The diagnosis is straight forward in those presenting with hydrophobia 
after bite by a rabid animal. But rabies should be suspected in every 
individual presenting with progressive encephalitis regardless of the history 
of dog bite or exposure. Ante mortem diagnosis of rabies viral infection 
requires several specimens like saliva, serum, urine, and CSF, and also 
requires multiple testing modalities because none of the test is highly 
sensitive and the viral shedding can be intermittent. 
Direct fluorescent antibody staining of biopsy material mainly from the 
nape of the neck above the hairline because the viral tends to localize in those 
hair follicles because it is richly innervated by nerve fibers. During the first 
week about 50% of samples reveal rabies the percentage stars increasing after 
that. 
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Reverse transcriptase – polymerase chain reaction [RT-PCR]: 
It can be performed on CSF, saliva, and on tissues. It allows 
geographic and host species origin of particular rabies virus. It can also be 
performed on decomposed brain tissues. The sensitivity of saliva sample can 
be increased to 100% if three samples can be obtained and tested. 
 
 
The rapid fluorescent focus inhibition test [RFFIT] is a test for virus 
neutralizing antibodies,50% develop these antibodies in detectable though not 
protective levels by day 8 and 100% by day 15. Any amount of antibodies 
levels in CSF is diagnostic even though the patient has received the post 
exposure prophylaxis.  
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If no active or passive immunization has been given, the presence of 
antibodies to rabies virus in serum is diagnostic. But if the person has been 
given vaccination second serum sample has to be obtained few days to 
demonstrate the increase in titers for diagnosis. However irrespective of 
vaccination status of the individual antibodies in CSF is diagnostic of 
infection.  
 
          Imaging studies are not specific for rabies. MRI brain can show 
increased T2 weighted signal intensities in hippocampus, hypothalamus and 
brainstem regions 
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ADVANTAGES AND LIMITATIONS OF INVESTIGATIONS  
FOR RABIES: 
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PREVENTION: 
 
With no effective treatment options available once the disease is 
confirmed, the main stay of focus is on prevention by means of pre as well as 
post exposure prophylaxis 
 
DIFFERENT VACCINATION PREPARATIONS: 
 
Louis pastuer pioneered the work on rabies vaccination. In 1885 
Pauster successfully immunized the first patient Joseph Meister with his 
rabies vaccine. In 1911 Sir David Semple prepared an inactivated carbolized 
vaccine that was derived from infected animal nervous tissues which became 
Semple vaccine. This was used in many countries for many years. Due to 
frequent neuroparalytic complications this vaccine was not used now a days. 
 
Now only cell cultured vaccines and purified duck embryo vaccine are 
used. The neurotropic vaccine in India was stopped since December 
2004.“Anti-rabies vaccines are produced as one single intramuscular dose 
with potency of > 2.5IU per IM dose for post exposure and pre-exposure 
prophylaxis. It is absolutely essential that every batch of cell culture vaccine 
or purified duck embryo vaccine have minimum potency of 2.5IU per 
intramuscular dose”. 
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The vaccine can be given either intra dermal or intra muscular route. 
The vaccine are available in both freeze dried lyophilized as well as liquid 
adsorbed forms. Shifting from one brand or type of vaccines are not 
encouraged, but in case of unavoidable situations this adjustments are not 
forbidden. 
 
CURRENTLY AVAILABLE ANTIRABIES VACCINES IN INDIA: 
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VACCINES APPROVED FOR ID USE IN OUR COUNTRY: 
Only the vaccines approved by DCGI for intradermal route should be 
used for intra dermal route. Irrespective of reconstituted volume each dose at 
single intra dermal site should consist of 0.1ml of vaccine. Once reconstituted 
vaccine should be used within 8 hours. During that period the reconstituted 
vaccine should be stored at a temperature of 2-8ºC. Intra dermal route for 
anti-rabies vaccination was by world health organization since the year 1992. 
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VACCINES APPROVED FOR IM ROUTE IN OUR COUNTRY: 
1. Human diploid cell vaccine-HDCV, liquid [adsorbed] 1ml 
2. Purified chick embryo cell vaccine - PCECV 1ml 
3. Purified Vero cell culture vaccine – PVCV o.5ml and 1 ml 
4. Purified duck embryo vaccine –PDEV 1 ml Of the above four, the 
first three vaccines are cell cultured vaccines 
 
PRE-EXPOSURE PROPHYLAXIS: 
It may be offered to those high risk individuals like 
 
1. Laboratory staff handling the virus and infected material 
2. Clinicians and health care workers handling human rabies cases 
3. Veterinarians 
4. Animal handlers and animal catchers 
5. Quarantine officers 
6. Travelers from rabies free areas to rabies endemic areas 
 
            The Indian academy of pediatrics recommended pre exposure 
prophylaxis to children on voluntary basis.  
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SCHEDULE: 
 
 
 
POST EXPOSURE PROPHYLAXIS: 
It has to be approached in a stepwise manner. Three steps has to be 
given equal importance and should be followed in a stepwise manner as far as 
possible. 
          1. Categorization of animal bite wounds and proper wound 
management. 
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          2. Passive immunization with rabies immunoglobulin either with 
human or equine origin. 
 
          3. Active immunization with anti-rabies vaccination. 
 
It should be emphasized that post exposure prophylaxis should be 
started as soon as possible after the exposure. However it should not be 
denied to those presenting late. 
 
It is one of the few conditions that both active and passive 
immunizations are given on the same time but at different sites. 
  
Post exposure is the main stay in preventing rabies since no effective 
treatment options available. When administered properly it is nearly always 
100% effective. Local multiplication of rabies virus before entering into the 
nervous system gives us the time for post exposure prophylaxis. 
 
World health organization has classified wounds into three categories 
regarding post exposure prophylaxis 
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WHO WOUND CLASSIFICATION REGARDING POST EXPOSURE 
PROPHYLAXIS: 
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WOUND MANAGEMENT: 
It mainly consists of these steps  
            1. Physical treatment 
                    2. Chemical treatment 
                    3. Tetanus prophylaxis 
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PHYSICAL MANAGEMENT: 
Wound toilet should be done by prompt and gentle washing under 
running water. It should be done for 15 to 20 minutes. It should be kept in 
mind that wounds should not be handled with bare hands all the time. Sterile 
gloves should be used. The wound washing should not be denied to those 
persons presenting late if the wound is unhealthy. The benefit for fresh 
wounds is maximum when compared with the old and unhealthy wounds. 
 
CHEMICAL MANAGEMENT: 
Followed by wound toileting with running water, wounds should be 
treated with soap and detergents because virus is inactivated by the above 
agents. Then antiseptics can be applied. Antiseptics like iodine and alcohol 
can be used. The application of the irritants to the wounds is unnecessary and 
it can be damaging. 
 
SUTURING: 
Suturing of wounds should be avoided as far as possible. But if 
surgically unavoidable after adequate wound washing and local infiltration 
with passive immunization loose sutures can be applied after delaying for 
several hours. The delay in suturing and lose sutures helps in diffusion of 
antibodies into the tissues. 
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PASSIVE IMMUNISATION: 
The anti-rabies immunoglobulin both human as well as the equine can 
be used for passive immunization. They provide the readymade antibodies 
that can bind with the viruses in the muscle tissue before it gains entry into 
the nervous system. They tie over the period required for the production of 
antibodies by means of active immunization. 
 
WOUND CAUTERISATION: 
It is contraindicated because it leads to bad scar formation as well as it 
does not contain any additional benefits. 
 
TETANUS PROPHYLAXIS: 
           If required tetanus prophylaxis should be provided to prevent the 
sepsis and a course of antibiotics can be prescribed if needed. 
 
ANTIRABIES IMMUNOGLOBULIN:  
          Human antirabies immunoglobulin:  20IU/Kg dose 
          Equine antirabies immunoglobulin:  40IU/Kg dose 
Human antirabies immunoglobulin is preferred over equine whenever 
available because of homologous origin and free of side effects encounter in 
when using heterologous origin like equine immunoglobulin. Because of the 
longer half-life only half the dose required for equine immunoglobulin is 
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used. The main limiting factor for its use is the cost. It was in 1890 BABES 
demonstrated the usefulness of anti-rabies immunoglobulin in experimental 
animals. And then till 1960 equine immunoglobulin was used but it was not 
purified and this leads to many adverse effects. Now highly purified and 
enzyme digested ERIG are available leading to very much less adverse 
effects. 
The use of human serum for making rabies immunoglobulin was 
introduced by HOSTY in 1959. By 1971 CABASSO made standardization in 
the production of human antirabies immunoglobulin and determined the 
optimal dose required for passive immunization. 
 
EQUINE ANTIRABIES IMMNUGLOBULIN: 
ERIG is produced by hyperimmunisation. They contain highly purified 
Fab2’ fragments. There is possibility of adverse effects because of its 
heterologous origin but it is virtually zero by means of highly purified 
techniques. However literature evidences support that skin testing prior to 
administration does not predict anaphylactic reactions. There is also need to 
give equine immunoglobulin if human immunoglobulin is not available. 
Therefore routine skin testing is not recommended. The treating physician 
should be prepared to manage anaphylaxis even though rare it can occur at 
any stage of administration. 
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INDICATION OF PASSIVE IMMUNISATION: 
1. All category III exposures 
2. Bites by wild animals 
3. Additionally in Category II exposures of immunocompromised 
individuals  
• If an individual consumed the milk of a the rabid animal 
without boiling full dose of immunoglobulin has to given via 
IM route followed by full course of rabies vaccination 
• Following sexual exposure with a human rabies patient full 
dose of immunoglobulin has to be given via IM route 
followed by full course of rabies vaccination. 
 
There is no contraindication for immunoglobulin use in pregnant and 
lactating females. The dosage of immunoglobulin should not exceed the 
recommended dose calculated. It should be infiltrated immediately as 
possible soon after the cleaning of wounds. It can be given along with rabies 
vaccination but at a different site. However if only rabies vaccination alone 
was started initially, the immunoglobulin can be given up to 7 days after 
starting the first dose. After that period it will interfere with the production of 
antibody stimulated by means of active immunization. Hence it is not 
advisable to give immunoglobulin 7 days after starting active immunization. 
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By this time antibody production by active immunization will start and able 
to protect the individual.  
 
ADMINISTRATION OF IMMUNOGLOBULIN: 
Before administration the immunoglobulin must be brought to room 
temperature. It is important to infiltrate all immunoglobulin to al wounds to 
neutralize the virus locally. Systemic administration via IM route is of very 
little value. The total dose of immunoglobulin calculated should be infiltrated 
as anatomically feasible, into and around all wounds. 
 
 During injection of immunoglobulin the piston of syringe should be 
pushed slowly while withdrawing the needle to ensure that the entire 
thickness of the wound is infiltrated. It is preferable to use separate injections 
for different wound sites. Multiple injections into the same wound should be 
avoided as far as possible. Care should be taken to in avoiding compartment 
syndrome while injecting immunoglobulin in fingertips and toes. After 
infiltrating all areas if small volume of immunoglobulin is left it can be given 
systemically via IM route at a distant site. Gluteal route should be avoided. 
            
Rabies immunoglobulin can be diluted with sterile normal saline if the 
requirement for infiltration is high.  
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• If the exposure involves the eyes, the immunoglobulin can be 
used as eye drops. For this purpose it has to diluted with 
normal saline in the ratio of 1:1 
• If the wound is sutured because of severe blood loss or in any 
unavoidable situations rabies immunoglobulin can still be 
given into the sutured wounds without disturbing the sutures. 
In those cases it can be seen to ooze from the wound site after 
injection. If too much oozing is seen it has to be compensated 
• In cases of already infected wounds immunoglobulin can be 
administered after thorough cleaning. 
• It should never be given via intra venous route.  
 
Erythema and serum sickness may develop following rabies 
immunoglobulin administration in 1 to 2% of patients after six days. In that 
case antihistamines and non-steroidal anti-inflammatory drugs are sufficient. 
They are observed in equine immunoglobulin not during human 
immunoglobulin administration. 
 
 
POST EXPOSURE PROPHYLAXIS [ACTIVE IMMUNISATION]: 
          The two types of vaccines now available in India are 
1. Tissue cultured vaccine 
2. Purified duck embryo vaccine 
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It can be via either intramuscular or intradermal methods. There are 
many regimens for vaccination which evolved over time. The number of 
doses required becoming less and less. The number of days required for 
vaccination also been reduced over the time. All of these are achieved mainly 
because of the development of more potent vaccines and development made 
in understanding the immunological basis of active immunization for rabies. 
 
INTRA MUSCULAR REGIMEN: 
The approved regimen for intramuscular route are 
1. Essen regimen 
2. Zagreb schedule 
 
 
ESSEN REGIMEN: 
There are two recommendations regarding this regimen 
1. World health organization recommendation 
2. Center for disease control – Advisory Committee on 
Immunization Practices.  
 
 
WHO RECOMMENDATION: [1-1-1-1-1] 
 WHO recommends five dose intramuscular regimen. It consists of five 
doses of recommended amount of approved vaccines via intramuscular 
administration. The days the vaccines should be given are 0, 3, 7, 14, and 28. 
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The sixth dose on day 90 should be considered optional for individuals who 
are immunologically deficient, those who are in extremes of age and who are 
all on immunosuppressive therapies. The day ‘0’ indicates the date of first 
dose of vaccination and not the day of dog bite. The vaccines should be given 
in deltoid region. Gluteal region is to be avoided because of higher fat layer 
and chances of vaccines being deposited in fat is higher when compared to 
deltoid region. The vaccine must be deposited in muscle for inducing 
immunogenicity. For children who are less than 2 years of age the vaccines 
are to be given in the anterolateral aspect of thigh. 
 
CDC – ACIP RECOMMENDATIONS: [1-1-1-1] 
The CDC - ACIP on 2010 came with the recommendation that the fifth 
dose on day 28 is not needed based on the retrospective analysis of the data. 
The regimen now being followed in United States of America is four dose 
regimen via intramuscular route on days 0, 3, 7, and 14. The doses on 28th 
and 90th days are given for those on extremes of ages, those who are on 
immunosuppressive therapies and who are immunodeficient. The 
recommendation regarding immunoglobulin use by WHO is not changed. 
 
ZAGREB REGIMEN: [2-1-1] 
Abbreviated multisite intramuscular regimen. It consists of two doses 
of vaccines on day ‘0’, one dose on each deltoid on day ‘0’. Followed by one 
46 
 
dose of vaccine on day 7 and day 21. By means of this schedule number of 
visits and doses of vaccines are also reduced. The WHO also approved this 
regimen. 
 
SPECIAL SITUATIONS: [2-1-1-1-1] 
In conditions where immunoglobulin is not available there should be 
more emphasis on proper wound toileting, this should be followed by Essen 
regimen of tissue culture vaccination with double dose of vaccine on day ‘0’ 
at 2 different sites intramuscularly. The remaining doses on days 3, 7, 14 and 
28. The doubling the dose of vaccine on first day is done for faster induction 
of immune system in producing the antibodies. But it should be greatly 
emphasized that doubling the dose on the first day is not a replacement to 
immunoglobulin. 
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INTRADERMAL REGIMEN: 
There are three regimens for intradermal vaccination schedule 
1. Updated Thai Red Cross schedule 
2. Oxford – eight site intradermal regimen 
3. Four site intradermal regimen 
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UPDATED THAI RED CROSS REGIMEN: [2-2-2-0-2] 
One dose of vaccine, that is o.1ml/0.2 ml of vaccine is given at two 
different lymphatic drainage sites usually in the right and left upper arm on 
days 0, 3, 7, and 28.The day ‘0’ corresponds to the day of vaccination not the 
day of dog bite. 
The vaccines approved for this regimen in India is  
1. Purified vero cell vaccine 
2. Purified chick embryo cell vaccine 
 
8 SITE INTRADERMAL REGIMEN–OXFORD REGIMEN [8-0-4-0-1-1] 
It consist of one dose of 0.1ml of vaccine administered at eight 
different lymphatic drainage system – two upper arms, two thighs, either side 
on lower quadrant of abdomen, both suprascapular region on day ‘0’. Then 
on day ‘7’ four o.1ml on arms and thigh region. Followed by one injection on 
0.1 ml in arm on days 28 and 90. The day ‘0’ corresponds to the day of 
vaccination and the day of vaccination. 
The vaccines approved for this regimen are  
1. Human diploid cell vaccine 
2. Purified chick embryo cell vaccine 
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FOUR SITE INTRADERMAL REGIMEN: [4-0-2-0-1]: 
The vaccines approved for this use are 
1. purified vero cell vaccine 
2. purified chick embryo cell vaccine 
             It consist of four doses of 01.ml/0.2ml of vaccine on day ‘0’. Each 
dose to be injected intradermally at four different lymphatic drainage sites. 
On day 7 it consist of two doses at two different sites. On day 28 it consist of 
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one dose of vaccine. Here also the day ‘0’ corresponds to day of vaccination 
not the day of dog bite. 
NOTE:  in cases of highly potent vaccine like purified vero cell culture 
vaccine each dose of vaccine is 0.1ml but in cases of other vaccines the dose 
of each vaccine is 0.2 ml 
 
VACCINE STORAGE RECONSTITUTION AND USAGE: 
Anti-rabies vaccines are available in both liquid form and in 
lyophilized form. Though lyophilized form is stable to mild temperature 
changes it has to be stored at 2-8o C. Even though freezing does not damages 
the lyophilized powder there is a chance that ampoule containing diluent may 
break. Liquid vaccines should never be allowed to be frozen. 
 
         The lyophilized vaccines should be reconstituted with the diluent 
provided immediately prior to the usage. Once reconstituted the vaccines 
should be used within 6-8 hours. Otherwise it has to be discarded. During 
those periods it has to be stored in a refrigerator. 
 
Switching from one brand to another brand during the course of 
vaccination is not recommended. “Currently anti rabies vaccines are 
produced as one intra muscular dose with potency of greater or equal to 
2.5IU per IM dose for both pre as well as post exposure prophylaxis”. It is 
absolutely essential that every batch of   cell cultured or purified duck 
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embryo vaccine should have a potency of above said levels for its use in 
general population. 
 
MECHANISM OF ACTIVATION OF IMMUNE SYSTEM: 
When vaccines are given via intramuscular route the antigen gets 
deposited in the muscle. After that it is absorbed by the blood vessels and 
then presented to the antigen presenting cells which then activates the 
immune system. The amount of vaccine required for the activation of 
immune system is more when compared to the intradermal dose. It thus have 
a large economic concerns. 
 
         When vaccines are given via intradermal route at multiple lymphatic 
drainage sites its gets deposited in the dermal layer of the skin. The antigen is 
directly carried by the antigen presenting cells via the lymphatics to the 
regional lymph nodes and regional reticulo endothelial system there by 
eliciting prompt and protective antibody response. When given via 
intradermal route the amount of vaccine required to elicit the immune 
response is only a fraction of the level required when given via intramuscular 
route. It is actually one fifth to one tenth of dose of intramuscular route. 
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        When using the intra dermal route the countries able to cover large 
population with the limited quantities available. This is especially useful in 
cases of economically constrained countries. 
 
Based on the above said facts who recommends the vaccination against 
rabies via intradermal route from 1992 onwards.  India has also adopted the 
WHO recommendation. 
 
RESPONSE TO IMMUNISATION: 
Early experiment studies revealed that the inactivated viruses used in 
the active immunization leads to the stimulation of the production of 
cytotoxic T – cells. There is also contradicting evidence to this observation, 
the depletion of cytotoxic T – cells in experimental mice had no effect against 
rabies virus protection nor in the survival rate of vaccinated animals. This 
evidences points out that cytotoxic T – cells alone not responsible for 
protection against rabies. There is also evidences pointing to the involvement 
of B – cells as wells as CD4+ helper cells via MHC II mechanisms. These 
leads to the activation of lymphocytes and antibody producing plasmocytes. 
Thus rabies virus neutralizing antibodies are produced. Then they migrate to 
the neural parenchyma. CD4+ T lymphocytes activation plays an important 
role in the protection against rabies virus via vaccination. Thus both humoral 
and cell mediated immunity plays a vital role in the protection against rabies. 
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The role of cell mediated and humoral immunity is studied in human 
models also by comparing immune response pattern with those having 
combined B cell and T cell immunodeficiency. The healthy individuals 
produced significant increase in the rabies virus immunoglobulin of IgM type 
starting one week after vaccination. Then one week later there is also 
significant increase in the IgG type also specifically IgG1 and IgG3. The 
above antibodies are measured using ELISA technique. Then after the 
booster dose the levels of IgG levels increases more than it does following 
the primary vaccination. This response is measured one week after the 
booster dose. Overall IgG1 plays an important role in the rabies immunity 
both in the primary as well as booster vaccination.  In the same study 
involving the B and Tcell immunodeficient individuals they found number of 
abnormalities in the immune response. 
 
Following inoculation the virus either multiply in the muscle before 
entering into the peripheral nervous system or it can directly enter the 
nervous system. The clear-cut pathological mechanism is yet to understood. 
Once the rabies virus gains entry into the nervous system the prognosis is 
always nearly fatal. Thus highlighting the importance of rabies 
immunoglobulin in post exposure prophylaxis. There is evidence also that 
even after rabies virus entry into the nervous system neutralization is still 
possible which is supported by the fact that active immunization given after 
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several days to months can still able to protect the individual. This forms the 
basis that rabies immunization should not be denied for those who are 
presenting late. Thus it can be taken that rabies virus antibodies can 
occasionally clear virus from the central nervous system. 
 
After the active immunization against rabies the antibodies are 
produced against the various components of the viral proteins specifically G 
and N components. The experimental evidences indicate that antibodies 
directed against N component alone do not confer protection even though 
they are the main components raised after the immunization. The role of non-
neutralizing antibodies against the rabies virus is not clearly understood till 
now. There is no specific protective rabies virus neutralizing antibody levels 
that can be named as protective. Most of us consider that an antibody level of 
0.5 IU/ml is protective. The WHO has given this level only as a proof of 
adequate immune response not as the protective level. 
 
Those who are taking steroids, anti-malarials especially chloroquine, 
immune compromised should receive active immunization via intramuscular 
route and not via intradermal route, as well those who are on extremes of age. 
They might also require addition doses of vaccines. These are peoples where 
testing of antibody levels will be very much useful. 
 
  TECHNIQUE OF INTRADERMAL VACCINATION:
As said above that the individual should not be 
or should not be on any immunosuppressive drugs, chloroquine when 
planned to receive the vaccination via in
The vaccines approved for intradermal route only should be used.  If 
the vaccine used is lyophilized vaccine it has to reconstituted with the diluent 
provided by the manufacturer in the prescribed amount 
with the 24G needle. The reconstituted volume is 1ml mostly. 
 
The vaccine dose to be given at one site is o.1ml in case of vero cell 
vaccine and 0.2ml in cases of less potent other cell culture vaccines and 
purified duck embryo vaccine. 
reconstituted volume used for reconstitution.
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immune 
 tradermal rote. 
using 2ml syringe 
This amount is constant irrespective of the 
 
compromised 
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For intradermal vaccination it preferable to use either 20 units or 40 
units insulin syringe with 29G needle. Because of less painful experience as 
well as entering the dermal layer will be easier when compared with the 
standard intramuscular syringes. It should be the self-mounted needle to 
decrease the vaccine wastage when compared to the detachable needles. 
 
1 ml 40 UNITS INSULIN SYRINGE: 4 units equals 0.1ml 
0.5 ml 20 UNITS INSULIN SYRINGE: 4 units equals 0.1 ml 
 
Depending upon the vaccines used 4 or 8 units of vaccine will be taken 
in the insulin syringe after sterile aseptic precautions. Air should be let out 
before the injection to avoid dead space in the injection. Then using the BCG 
injection technique the needle is inserted parallel to the skin after stretching 
the skin surface. The bevel should face upwards at the time of injection. If the 
needle is correctly placed in the dermal layer there will be resistance to the 
injection. A bleb should be raised after successful injection into the dermal 
layer. Surface of the skin will show the puckering and feel like peel of the 
orange “peau d’ orange”. 
 
If the vaccine is injected deep into the subcutaneous layer it will not 
raise the bleb. Then the needle should be withdrawn and injected at a 
different site once more. 
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The sites used for intradermal injection are 
1. over the deltoid  region 
2. suprascapular region 
3. anterior aspect of thigh region 
4. lower quadrants of abdomen 
 
 After injection do not rub or apply anything to the injection site. 
 Advice the patient about the need for the completion of vaccination 
for the effective immune response. 
 
ADVERSE REACTIONS: 
 Mild adverse reactions like itching and erythema, fever can occur in 
small number of patients. They are self-limiting and life threatening. 
Symptomatic management like analgesics and anti-histamines are usually 
sufficient. Steroids should be avoided as they interfere with the immune 
response 
 
NOTE:   switching over from one brand to another brand of vaccine 
during the course of vaccination is not recommended. 
 
          Switching from one route of administration to another during the 
course of vaccination like from intradermal to intramuscular or vice versa is 
not recommended. 
  
GUIDE TO POST EXPOSURE PROPHYLAXIS:
 
 
POST EXPOSURE PROPHYLAXIS OF PREVIOUSLY 
VACCINATED INDIVIDUALS:
For those individuals who are vaccinated previously by means either 
pre exposure or post exposure prophylaxis on re
of the following methods recommended below
 
59 
 
 
-exposure should receive one 
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1. IM booster regimen 0, 3 day regimen 
2. ID  booster regimen 0, 3 day regimen 
3. Single day 4 site ID booster regimen 
 
IM BOOSTER REGIMEN: 
 The two booster via intramuscular route on day 0 and day three 
produces effective anamnestic response regarding antibody production. This 
regimen was approved by WHO since 1992. 
 
ID REGIMENS: 
 Similar to intramuscular route vaccination days the vaccines are given 
on day 0, and 3. The dose being 0.1ml in case of purified vero cell culture 
vaccine and 0.2ml in case of other vaccines. They are given at only one site. 
Even though the seroconversion rate is slower when compared to 
intramuscular route this regimen was approved by WHO since 1992. 
 There is an alternative single day regimen when using intradermal 
route. It consists of four doses of vaccines at four ID sites on the same day. 
This regime is also approved by WHO 
 
 NOTE: Rabies immunoglobulin is not needed for those individuals 
who are previously vaccinated by tissue cultured or purified duck embryo cell 
vaccine. 
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 Because the rabies immunoglobulin will suppress the anamnestic 
response. But if neuro trophic vaccines were used during pre-exposure or 
post exposure prophylaxis that individual should receive rabies 
immunoglobulin during re-exposure like the vaccine naïve individual.  When 
the individual has no memory regarding the vaccine type used during 
previous vaccination or when there is no records available of prior 
vaccination they require rabies immunoglobulin during re-exposure. 
 
          Booster doses are recommended every 6 months for those individuals 
who are at very high risk like those working in rabies virus laboratories. 
Every 6 months they has to undergo rabies virus neutralizing antibody testing 
and if the levels are below the protective levels booster doses are required. 
          
 For those individuals having frequent contacts with animals booster 
doses are required every two years once. For others no booster doses are 
routinely required. 
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NOTE: 
 When persons are vaccinated via intradermal route the amount of 
neutralizing antibody attained is higher as well as the immunological memory 
persist longer when compared to persons received the vaccine via 
intramuscular route. But when booster doses are needed the vaccine given via 
intramuscular route induces rapid anamnestic response when compared to 
intradermal route. Because of the concerns in the technique of the intradermal 
injection and multiple punctures needed intramuscular route is adopted by the 
developed nations. When giving intradermal injection instead of depositing in 
the dermal layer if the vaccine is deposited in the muscle layer it will not lead 
to effective stimulation of immune system because intradermal route uses 
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only a fraction of dose of intramuscular route. But there are reports despite of 
above concerns intradermal vaccination against rabies is being effectively 
implanted in many countries including India. 
 
RABIES TRAETMENT:  
 Till now there is no effective treatment options available once the 
diagnosis is made. There is protocol called “Milwaukee Protocol or 
Wisconsin protocol” which claimed to be the best treatment option 
available, but it fails to produce any beneficial effects in clinical experimental 
studies. Till now there are seven human rabies documented to be survived but 
based on the personal communications two of them found to be dead. So at 
present there are only five human rabies survivors. Of those five survivors 
there is only one personal with complete recovery, others are having mild to 
severe neurological sequelae. In all those documented recoveries post 
exposure vaccination was given to all of them except one. One of those 
survivors is a laboratory worker who exposed to live rabies virus has already 
underwent pre exposure vaccination. 
 
           All the human rabies case survivors are diagnosed on the basis of 
rabies virus neutralizing antibodies in the CSF. No rabies virus was isolated 
from their skin biopsy or corneal smear except one individual. From that 
individual rabies viral RNA was isolated from the skin biopsy. 
64 
 
            There also two reports of rabies viral antibodies present in the CSF 
without the presence of rabies viral neutralizing antibodies in their CSF. They 
did not any clinical symptoms suggestive of rabies. There was no contact 
history elicited from them. The exact etiology and pathogenesis remain 
unclear. 
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NOTE: 
 In the above mentioned human rabies cases the second case in 
1972, the vaccine used in the post exposure prophylaxis is 
neurotropic vaccine. This patient also showed prominent cerebellar 
sighs even though the rabies virus can infect the cerebellum human 
rabies patients will not show clinical manifestations of cerebellum. 
It should be also noted that this patient attained almost complete 
recovery with very minimal neurological sequelae. This also 
sparkles the thinking that this could be a case of neuroparalytic 
complications of neurotropic vaccination rather than a case of 
human rabies. 
 In the above mentioned cases the third case in a laboratory personal 
who has already completed pre exposure prophylaxis exposed while 
working with live rabies virus via aerosol route was the only 
documented case of rabies occurring in pre exposure vaccine 
completed individual. It is also a fourth cases reported for aerosol 
transmission of rabies virus. Another point to be noted in this case 
is he has is neutralizing antibody levels of about 32 IU/ml before 6 
months of his infection. This strongly emphasizes that there are no 
clear cut antibody protection level for rabies prevention. The level 
that is quoted by WHO is to measure the adequate immune 
response. 
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TREATMENT OPTIONS: 
1. RABIES VACCINES 
2. RABIES IMMUNOGLOBULIN 
3. KETAMINE 
4. INTERFERON – α 
5. RABIES MONOCLONAL ANTIBODIES 
6. CORTICOSTEROIDS 
 
RABIES VACCINES: 
 In animals survival from rabies encephalitis is associated with immune 
response. So in order to stimulate the immune response both humoral and cell 
mediated rabies vaccination was tried in human rabies patients but there was 
no beneficial effects observed. Since immune response after vaccination via 
intramuscular route vaccines were given via intradermal route at multiple 
sites for faster immune response but this also results in no beneficial effects. 
The fault may lies in the fact that attenuated vaccines or recombinant 
vaccines are for animal vaccination which leads to the stimulation of 
cytotoxic T cells whereas in case of human beings inactivated rabies vaccines 
are used and it does not leads to the stimulation of cytotoxic T cells . Till 
today there was no live attenuated or recombinant anti rabies vaccines were 
licensed for human use. 
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ANTIRABIES IMMUNOGLOBULIN: 
 This is based the hope that rabies immunoglobulin would promote the 
clearance of the rabies virus but it fails in clinical experiments. The full dose 
of immunoglobulin is given via intramuscular route in the human rabies cases 
because the virus has already gained the entry into the nervous system so 
local infiltration will not be much useful in those cases. It was once believed 
that higher than dose required for the post exposure prophylaxis was needed 
for the treatment of human rabies cases. But it also failed to achieve the 
positive results. 
 
 There is also concern thatimmunoglobulins will not enter the blood 
brain barrier when given via intramuscular route. But the effects and safety 
concerns of anti-rabies immunoglobulin via intra thecal route was unknown. 
There are reports that administration via intra thecal route will cause severe 
brain edema which could results in serious immediate adverse outcomes. 
 
 MONOCLONAL ANTIBODIES: 
 In experimental animal studies it was shown that rabies 
MONOCLONAL ANTIBODY 1112-1 clears the virus from the central 
nervous system when administered before the development of clinical 
symptoms. It thus leads to the survival of experimentally infected animals. 
These studies were carried out in rodent model. This shows promising but 
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human monoclonal antibody or humanized will be a better than mouse 
monoclonal antibodies. In future this holds promising. As of now it is still in 
the experimental stages only. 
 
RIBAVIRIN: 
 1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. It is a purine 
analogue. It is also a RNA mutagen. By acting as a template for cytidine and 
uridine it induces mutations in the viral genome. It also has 
immunomodulatory properties. It also demonstrates in vitro activity against 
the rabies virus. But in vivo efficacy is still under debate. It is a broad 
spectrum antiviral agent. 
 
 It is given with both loading and maintenance dose via intravenous 
route.  It will enter the intact blood brain barrier which is evidenced in animal 
studies. But in cases of infection the barrier appears to be not intact and there 
is uptake of ribavirin across the barrier. In order to overcome this uncertainty 
ribavirin can be given via intra thecal route by means of OMMAYA 
reservoir. Combined intravenous and intra thecal route also tried but 
apparently with no benefit. 
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INTERFERON-α: 
 It is immunoregulatory protein. It is used in both viral infections as 
well as in neoplasms. It creates an intracellular environment that interferes 
with replication of the viruses. It also interacts with the innate immune 
system and aid in the antigen presentation and also in the activation of 
cytotoxic T cells. It may also interact synergically with the antibodies. 
Experiment studies in the monkeys have demonstrated the beneficial effects. 
But if fails to reproduce in human beings. 
 
KETAMINE: 
          It is a dissociative anesthetic drug. It causes both sedation and 
analgesia. It also rapidly causes the blood brain barrier. It also a non-
competitive antagonist at NMDA receptor. 
 
 There also evidence based on animal studies that ketamine has got in 
vitro antiviral activity by inhibiting viral replication. It does it by inhibiting 
viral genome transcription. Based on these it was proposed that NMDA 
receptors may act as a receptor for rabies virus. But it fails to show consistent 
results. 
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CORTICOSTEROIDS: 
 In animal studies it was found to increase the mortality rates and it also 
shortens the incubation periods. Based on the above findings is not 
recommended for the management of severe brain edema, which by itself is a 
very rare finding due to rabies per se. Therefore it not recommended in the 
aggressive line of management of human rabies except in faces of adrenal 
insufficiency. Moreover it closes the blood brain barrier preventing the entry 
of other drugs. 
 
MILWAUKEE PROTOCOL: 
 It consist of the following steps  
1. Intubation and mechanical ventilation support 
2. Drug induced coma 
 Ketamine at doses of 48mg/kg/day in continuous intra 
venous infusion. 
 Midazolam infusion for 7 days 
3. Depending upon the EEG findings to suppress the bursts 
phenobarbital can be used 
4. Intravenous ribavirin 
5.  Amantadine 200 mg per day via enteral route 
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 The basis is to use neuroprotective agents and maintain life supports 
and wait for virus neutralizing antibodies to clear the rabies virus from the 
system. Even though the treatment appears to be beneficial it fails to produce 
similar results in the clinical practice. 
 
 In the next tabular column the documented treatment failures of 
patients treated with MILWAUKEE protocol are summarized. 
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CHANGE IN POST EXPOSURE PROPHYLAXIS OVER TIME: 
 Over the time post exposure vaccination schedule as well as the 
number of doses required has been changing. This is mainly because of our 
better understanding of the immune response to rabies vaccination when 
compared to the past and also because of the more potent vaccine 
developments. These modern day vaccines are free of major adverse effects 
when compared to the older vaccines. 
 
 
 There are also many human studies regarding the antibody levels 
following post exposure vaccination using various regimens and also with 
various vaccine preparations. Based on these studies only the center for 
disease control came with the latest recommendation of reduced four dose 
intra muscular regimen in 2010. Even though the post exposure vaccine 
regimens has changed over the course of time. The indication for anti-rabies 
immunoglobulin has not changed. 
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 There are many cases of vaccination failures documented in the 
literatures, but most of them are due to improper wound management and not 
following the schedules properly in applying immunoglobulin and as well as 
in vaccination. True vaccination per se is very rare.  
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GRAPHICAL REPRESENTATION OF VARIOUS STUDIES IN 
COMPARING ANTIBOBY TITERS ON DIFFERENT DAYS OF 
VACCINATION: 
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RAPID FLUORESCENT FOCUS INHIBITION TEST [RFFIT]: 
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STEPS INVOLVED IN THE RFFIT:  
 The serum to be tested is diluted  in a 96 well plate and transferred into 
a 8 –well chambered slides 
 Then the rabies challenge virus is added to the diluted serum 
 The slides are then incubated for 90 minutes 
 There after mouse neuroblastoma cells are added to each of the wells 
 Then the slides are incubated in an incubator for 20 to 24 hours 
 The incubator should be incubated at 370C and the CO2 concentration 
should be 2-5% 
 Then the slides are washed and fixed with 80% cold acetone 
 Then the FITC conjugated anti rabies virus antibody directed against 
rabies virus was added 
 Then the 20 fields of each well of 8 chambered slides are examined 
under the fluorescent microscope for the presence of fluorescence. If 
fluorescence is present it indicates the presence of non-neutralized 
virus infected cells 
 Then the 50% end point titer of serum is determined using REED – 
MEUNCH formula. 
 Then the potency of test serum is calculated in IU/ml using the formula 
 
79 
 
 
 KNOWLEDGE ATTITUDE AND PRACTICE REGARDING 
DOG BITE: 
 
 Since human rabies is nearly always fatal. The knowledge attitude 
practice regarding dog bite plays a vital role in the prevention of rabies. 
There are lots of misbeliefs and false practices regarding dot bites and its 
management. 
 
            Still there are many believing in the tradition practices over medical 
management for dog bites. But somehow they all seem to know about the 
observation period of the dogs in case of dog bite but they did not know the 
reason for observation. Mass media plays a big role in the instillation of these 
thoughts in their minds. They also think that medical management needed 
only for the unprovoked bites and for the bites by stray dogs only. Most of 
seem to me unaware about the transmission of rabies by wild animals and 
other animals. They also think that post exposure prophylaxis is not 
necessary for the bite by vaccinated pet dogs. There is also thought individual 
should observe food restriction for some particular time period. Similarly 
there is also thought that rabies spreads from human to human. 
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          Many KAP studies have been conducted to assess the knowledge 
attitude and practices among people regarding pet care, need for pet 
vaccination, dog bite managements. Surprisingly there is still lack of 
knowledge regarding dog bite management among treating physicians. This 
is mainly in the areas of current guidelines followed in the management of 
animal bites. 
 
 
 
  
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
SETTING: 
This study was conducted at the Anti-Rabies Vaccine Clinic, Rajiv 
Gandhi Government General Hospital and Madras Medical College. 
 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
 
STUDY DURATION: 
This study was conducted over a period of six months. 
 
STUDY POPULATION: 
   Patients coming to anti-rabies vaccine clinic for the post exposure 
prophylaxis management 
 
SAMPLE SIZE: 
100 patients 
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TYPE OF STUDY: 
Observational study 
 
INCLUSION CRITERIA: 
 New dog bite individuals with wounds belonging class, requiring 
both active and passive immunization. 
 
EXCLUSION CRITERIA: 
 
 History of previous dog bite. 
 
 History of anti-rabies vaccination or anti-rabies immunoglobulin in 
the past. 
 
 Other animal bites. 
 
 Clinical suspicion of rabies.  
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DATA COLLECTION AND METHODS 
 
 
Informed consent will be obtained from all the patients participating in 
the study. 
 
Patients have their history taken regarding the dog bite and then 
subjected to clinical examination of the wounds. 
 
The patients were given equine immunoglobulin at the dose of 40IU/kg 
locally infiltrated around the wound. Remaining if any is given at a distant 
site via intramuscular route. 
 
Then they are given 5 doses of 0.5ml of purified vero cell vaccine via 
intramuscular route on day 0, 3, 7, 14, and 28. The day ‘0’ being the day of 
vaccination and the day of dog bite. This regimen is approved by government 
of India 
 
The vaccine used in our hospital is ABHAYRAB – purified vero cell 
vaccine the anti-rabies immunoglobulin used in our hospital is EQUIRAB – 
equine anti rabies immunoglobulin. 
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            Then on the 14th day when the patient comes for the fourth dose of 
vaccination 5ml of venous blood sample is obtained prior to the fourth dose 
of vaccination. Then on the 21st day 5ml of venous sample is obtained. Each 
date of blood sampling collection corresponds to 7 days after respective doses 
of vaccination. 
 
Soon after the blood sample collection serum is separated under sterile 
aseptic precautions and then the sample is stored under -200C. After the 
collection samples from all 100 patients [totally 200 samples], serum anti 
rabies virus neutralizing antibody titers are measured using Rapid Fluorescent 
Focus Inhibition Test [RFFIT]. 
 
All the data will be entered in the Performa [enclosed]. 
Data will be analyzed using SPSS package and ANOVA. 
 
To the same individuals questionnaire comprising of 10 questions were 
given to assess their knowledge, attitude and practice regarding dog bite were 
given. Each correct response carries ‘1’ mark while the wrong question 
carries ‘0’ mark. The questionnaire consist of 5 questions assessing their 
knowledge and another 5 questions assessing their attitude and practice. 
All the data will be entered in the Performa [enclosed]. 
Data will be analyzed using SPSS package and ANOVA. 
  
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
 
AGE DISTRIBUTION IN THE STUDY GROUP: 
 
 Age in 
years Frequency Percent Valid Percent 
Cumulative 
Percent 
 
<= 20 9 9.0 9.0 9.0 
 
21-30 16 16.0 16.0 25.0 
 
31-40 13 13.0 13.0 38.0 
 
41-50 21 21.0 21.0 59.0 
 
51-60 21 21.0 21.0 80.0 
 
61-70 20 20.0 20.0 100.0 
 
Total 100 100.0 100.0  
 
 
 
 
 
  
 
 
 
 
 
 
9
16
0
5
10
15
20
25
<= 20 years 21-30 years
FREQUENCY OF AGE IN STUDY GROUP
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13
21 21
31-40 years 41-50 years 51-60 years
FREQUENCY
 
20
61-70 years
  
SEX DISTRIBUTION IN STUDY GROUP:
Gender Frequency
Male 73
Female 27
Total 100
 
 
 
87 
 
 Percent Valid Percent
 73.0 73.0 
 27.0 27.0 
 100.0 100.0 
 
73%
27%
TOTAL NUMBER
 
Cumulative 
Percent 
73.0 
100.0 
 
 
MALE
FEMALE
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DESCRIPTIVE STATISTICS 
 
RFFIT 
VALUES 
Number Of 
Individuals Minimum Maximum Mean 
Std. 
Deviation 
 AT 14TH  day 100 145.06 216.36 176.4822 17.29897 
 AT 21ST  day 100 163.04 226.35 200.6443 14.32372 
 
 
 
 
Paired Samples Statistics:   T-Test 
 
 
 
 
RFFIT 
VALUES  
AT 
Mean 
Number 
OF 
individuals 
Std. Deviation Std. Error Mean 
 
 
 
‘p’ value 
14th day 176.4822 100 17.29897 1.72990 
<0.001 
(HIGHLY 
SIGNIFICANT) 
21st day 200.6443 100 14.32372 1.43237 
 
  
 DESCRIPTIVE VALUES OF RFFIT
 
 
 
 
0
50
100
150
200
250
14TH DAY
145.06
DESCRIPTIVE VALUES OF RFFIT OBSERVED 
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MINIMUM VALUE
MAXIMUM VALUE
21ST DAY
163.04
216.36
226.35
MINIMUM VALUE MAXIMUM VALUE
 
  
MEAN RFFIT VALUES 
 
 
 
160
165
170
175
180
185
190
195
200
205
14TH DAY
90 
OBSERVED IN THE STUDY GROUP:
 
21ST DAY
176.48
200.64
MEAN VALUE
MEAN VALUE
 
 
MEAN 
VALUE
 FREQUENCY TABLE:
KNOWLEDGE QUESTIONNAIRE 1:
WHAT TREATMENT OPTIONS ARE AVAILABLE FOR DOG BITE?
 ANSWERS : P
active immunization. 
RESPONSE Frequency
Right 100
 
 
 
NUMBER OF INDIVIDULAS IN STUDY 
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ost exposure prophylaxis in the form of passive and 
 Percent Valid Percent 
 100.0 100.0 
 
GROUP
RIGHT WRONG
 
Cumulative 
Percent 
100.0 
 
  
KNOWLEDGE QUESTIONNAIRE 2:
WHAT IS THE MODE OF TRANSMISSION OF RABIES?
ANSWERS:  Through the bite of rabid animals.
RESPONSE Frequency
 
Right 100
 
 
 
NUMBER OF INDIVIDUALS IN THE STUDY 
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 Percent Valid Percent 
 
 
 
100.0 
 
100.0 
GROUP
RIGHT WRONG
 
Cumulative 
Percent 
 
100.0 
 
 KNOWLEDGE QUESTINNAIRE 3:
HOW MANY DAYS ONE SHOULD OBSERVE THE DOG 
FOLLOWING BITE AND WHAT FOR?
ANSWER: 10 DAYS. TO OBSERVE IF THE DOG DEVELOPS 
ANY SIGHS OF RABIES OR DIE WITHIN TEN DAYS DUE TO 
RABIES. 
 
 
RESPONSE Frequency
Right 
NUMBER OF INDIVIDUALS IN STUDY GROUP
93 
 
 
 
 Percent Valid Percent
100 100.0 100.0 
 
RIGHT WRONG
 
Cumulative 
Percent 
100.0 
 
 KNOWLEDGE QUESTIONNAIRE 4:
CHANCES OF SURVIVAL IF RABIES DEVELOPS?
ANSWER:  AT PRESENT NO.
 
RESPONSE FREQUENCY
RIGHT 93
WRONG 7
 
 
 
 
TOTAL NUMBER OF INDIVIDUALS
94 
 
 
 
 PERCENT 
VALID 
PERCENT 
CUMULATIVE 
 93 93 
 7 7 
 
93%
7%
PERCENT 
93 
7 
 
RIGHT
WRONG
 KNOWLEDGE QUESTIONNAIRE 5:
WILL RABIES SPREAD FROM HUMAN TO HUMAN?
ANSWER:  NO. 
RESPONSE FREQUENCY
RIGHT 13
WRONG 87
 
 
 
TOTRAL NUMBER OF INDIVIDUALS
95 
 
 PERCENT 
VALID 
PERCENT 
CUMULATIVE 
 13 13 
 87 87 
80%
20%
 
PERCENT 
13 
87 
 
RIGHT
WRONG
 ATTITUDE AND PRACTICE QUESTONNAIRE 1:
YOUR OPINION REGARING WOUND 
IMMEDIATE SUTURING?
ANSWER:  WOUND SHOULD BE WASHED WITH PLENTY OF 
WATER FOR 15 MINUTES AND THEN WITH IODINE OR ALCOHOL. 
WOUND SHOULD NOT BE SUTURED IMMEDIATELY.
RESPONSE FREQUENCY
RIGHT 100
 
TOTTAL NUMBER OF INDIVIDUALS
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WASHING AND 
 
 
 PERCENT VALID 
PERCENT 
CUMULATIVE 
 100 100 
RIGHT WRONG
PERCENT 
100 
 
 ATTITUDE AND PRACTICE QUESTONNAIRE 2:
YOUR OPINION REGARDING PROPHYLAXIS IN CASE OF 
PROVOKED DOG BITE?
ANSWER: YES, POST EXPOSURE PROPHYLAXIS SHOULD BE 
GIVEN. 
RESPONSE FREQUENCY
RIGHT 22
WRONG 78
 
 
TOTAL NUMBER OF INDIVIDUALS 
97 
 
 
 PERCENT 
VALID 
PERCENT 
CUMULATIVE 
 22 22 
 78 78 
 
22%
78%
PERCENT 
22 
78 
 
RIGHT
WRONG
 ATTITUDE AND PRACTICE QUESTONNAIRE 3:
WHETHER ALL DOSES OF ARV [ANTI RABIES AVCCINATION] 
IN THE PEP [POST EXPOSURE PROPHYLAXIS] SCHEDULE 
SHOULD BE COMPLETED?
ANSWERS:  YES, IT SHOULD BE COMPLETED ACCORDING TO THE 
REGIMEN 
RESPONSE FREQUENCY
RIGHT 49
WRONG 51
 
TOTAL NUMBER OF INDIVIDUALS
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 PERCENT VALID 
PERCENT 
CUMULATIVE 
 49 49 
 51 51 
49%51%
PERCENT 
49 
51 
 
RIGHT
WRONG
 ATTITUDE AND PRACTICE QUESTONNAIRE 4:
YOUR OPINON WHETHER PEP [POST EXPOSURE PROPHYLXIS] 
ARV [ANTI RABIES VACCINATION] NEEDED IN VACCINATED 
DOG BITES? 
ANSWERS:  YES 
RESPONSE FREQUENCY
RIGHT 22
WRONG 78
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 PERCENT 
VALID 
PERCENT 
CUMULATIVE 
 22 22 
 78 78 
22%
78%
Sales
PERCENT 
22 
78 
 
RIGHT
WRONG
 ATTITUDE AND PRACTICE QUESTONNAIRE 5:
WHETHER AVOIDENCE OF CERTAIN FOODS NEEDED AFTER 
DOGBITE FOR ANY PARTICULAR PERIOD?
ANSWER:  NO 
RESPONSE FREQUENCY
WRONG 100
 
 
 
 
TOTAL NUMBER OF INDIVIDUAL
100 
 
 
 PERCENT 
VALID 
PERCENT 
CUMULATIVE 
 100 100 
RIGHT
0%
WRONG
100%
PERCENT 
100 
 
101 
 
 
 
DESCRIPTIVE STATISTICS FOR KAP ANALYSIS: 
 
N
U
M
BE
R
 
O
F 
IN
D
IV
ID
U
A
LS
 
M
IN
IM
U
M
 
M
A
R
K
S 
M
A
X
IM
U
M
 
M
A
R
K
S 
M
EA
N
 
ST
A
N
D
A
R
D
 
D
EV
IA
TI
O
N
 
KNOWLEDGE SCORE 100 3 5 4.06 0.422 
ATTITUDE AND PRACTICE 
SCORE 
100 1 4 1.93 0.935 
TOTAL KAP SCORE 100 4 9 5.99 1.000 
 
  
  
 
 
0
1
2
3
4
5
6
7
8
9
KNOWLEDGE SCORE
DESCRIPTIVE REPRESENTATION OF KAP STUDY
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MINIMUM MARKS
ATTITUDE AND 
PRACTICE SCORE
TOTAL KAP SCORE
MINIMUM MARKS MAXIMUM MARKS
 
MAXIMUM MARKS
103 
 
 
SEX BASED DESCRIPTIVE STATISTICS FOR KAP SCORE: 
 
 SEX 
NUMBER OF 
INDIVIDUALS 
MEAN 
STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
‘p’ VALUE 
KNOWLEDGE 
SCORE 
MALE 73 4.05 0.437 0.51 0.303 
INSIGNIFICANT FEMALE 27 4.07 0.385 0.74 
ATTITUDE 
AND 
PRACTICE 
SCORE 
MALE 73 1.97 0.912 0.107 
0.054 
INSIGNIFICANT 
FEMALE 27 1.81 1.001 0.193 
TOTAL KAP 
SCORE 
MALE 73 6.03 0.986 0.115 0.124 
INSIGNIFICANT FEMALE 27 5.89 1.050 0.202 
 
 
 
 
 
     
  
104 
 
RESULTS 
AGE DISTRIBUTION: 
 In our study 9% of the individual are between 12 – 20 years. 16% of 
the individual are between 21-30 years. 13% of the individual are between 
31-40 years. 21% of individuals are between are between 41- 50 years. 21% 
of individuals are between 51-60 years. 20 % individuals are between 61-70 
years. The mean age in our study group is 44 years. 
 
SEX DISTRIBUTION: 
 In our study group males were 73% and females are 27%. 
 
CORRELATION BETWEEN ANTIBODY TITERS ON 14TH DAY AND 
21ST DAY: 
 The minimum titer of anti-rabies virus neutralizing antibody observed 
on 14th day is 145.06 IU/ml and the maximum antibody titer observed on 14th 
day is 216.36 IU/ml. The average antibody titer observed on 14th day is 
176.48 IU/ml 
 
          The minimum titer of anti-rabies virus neutralizing antibody observed 
on 21st day is 163.04 IU/ml and the maximum antibody titer observed on 
21stday is 226.35 IU/ml. the average antibody titer observed on 21st day is 
200.64 IU/ml 
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 When compared with 14th day [7 days after the third dose of 
intramuscular vaccination] the antibody titer rise on 21st day [7 days after 
fourth dose of intramuscular vaccination] is highly significant [‘p’ value 
<0.001]. 
 
KNOWLEDGE ATTITUDE AND PRACTICE ANALYSIS: 
 
KNOWLEDGE QUESTIONNAIRE: 
 
QUESTION 1: 
 100% of individuals gave the correct response. 
 
QUESTION 2: 
 100% of individuals gave the correct response. 
 
QUESTION 3: 
 100% of individuals gave the correct response. 
 
QUESTION 4: 
 93% of individuals gave the correct response.  
 7% of individuals gave the wrong response. 
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QUESTION 5: 
 13% of the individuals gave the correct response  
 87% of the individuals gave the wrong response. 
 
ATTITUDE AND PRACTICE QUESTIONNAIRE: 
QUESTION 1: 
 100% of the individuals gave the correct response. 
 
QUESTION 2: 
 22% of the individual gave the correct response. 
 78% of the individual gave the wrong response. 
 
QUESTION 3: 
 49% of the individual gave the correct response. 
 51% of the individual gave the wrong response. 
 
QUESTION 4: 
 22% of the individual gave the correct response. 
 78% of the individual gave the wrong response. 
 
QUESTION 5: 
 0% of the individual gave the correct response. 
 100% of the individuals gave the wrong response. 
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COMPARISON OF KNOWLEDGE ATTITUDE AND PRACTICE 
WITH AGE AND SEX DISTRIBUTION: 
 
 In the study group regarding knowledge questionnaire the minimum 
mark obtained by an individual is 3 out of 5. While the maximum mark 
obtained by an individual is 5 out of 5. The study group has an average of 
4.06 out of 5. 
  
 In the study group regarding attitude and practice questionnaire the 
minimum mark obtained by an individual is 1 out of 5. While the maximum 
mark obtained by an individual is 4 out of 5. The study group has an average 
of 1.93 out of 5. 
 
 The knowledge, attitude and practice regarding dog bite between sex 
and age distribution is INSIGNIFICANT [‘p’ value of 0.124]. 
 
 In our study of knowledge attitude and practice regarding dog bite, 
knowledge was adequate but the attitude and practice were inadequate and 
should be improved. 
 
 
  
 
 
 
DISCUSSION 
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DISCUSSION 
 
ALL THE STUDIES QUOTED BELOW HAS USED THE ANTI RABIES 
VACCINATION VIA INTRAMUSCULAR ROUTE. 
 
 In a study conducted in IRAN by BAHMANYAR et al on 45 persons 
bitten by rabid dogs and wolves human diploid cell vaccine was used. 
The vaccines were give as 6 doses on day 0, 3, 7, 14, 28 and 90. They 
observed that all develop adequate levels of antibodies after 4 doses. 
No immunoglobulin was used in the study. This was contrast to our 
study as our study group develop adequate antibodies after the third 
dose itself. 
 
  In a study conducted in GERMANY by KUWERT et al on 16 
volunteers using human diploid cell vaccine and immunoglobulin, the 
vaccines were given as 6 doses on day 0, 3, 7, 14, 28 and 90. They all 
develop adequate levels on day 14. This correlates with our study 
results. That our study group individuals develop adequate levels after 
3rd dose. But our study done on post exposure individuals not on 
healthy volunteers. 
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 In a study conducted in MANITOBE by AOKI FY et al on 24 healthy 
volunteers using human diploid cell vaccine along with 
immunoglobulin, the vaccines were given as 5 doses on day 0, 3, 7, 14 
and 28. They all develop adequate antibodies after 3rd dose and no 
increase in titer was observed after the 4th and 5th dose. This was 
contrast to our study because the increase in antibody titer between 
third and fourth dose was significant. 
 
  In a study conducted in MANITOBE by AKOI FY et al on both 
children and adult bitten by suspected rabid animal using human 
diploid cell vaccine along with immunoglobulin, the vaccines were 
given as 5 doses on day 0, 3, 7, 14 and 28. They all develop adequate 
antibodies after 3rd dose and no increase in titer was observed after the 
4th and 5th dose. In contrast, our study result showed that even after 3rd 
dose adequate antibody levels were reached. 
 
 In a study conducted in THAILAND by WASI.C et al on 27 children 
bitten by suspected rabid animals using purified chick embryo cell 
vaccine with or without immunoglobulin depending upon the class of 
wound, the vaccines were given as 6 doses on day 0, 3, 7, 14, 28 and 
90. They all develop adequate antibodies after 3 doses. This correlates 
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with our study result. But there was no comparison with the fourth 
dose. 
 
  In a study conducted in INDIA by BHATTACHARYA et al on 37 
individuals bitten by suspected rabid animals using purified vero cell 
vaccine, 3 doses of vaccines were given on day 0, 3 and 7. They all 
develop adequate antibodies after 3 doses. This correlates with our 
study result. But there was no comparison with the fourth dose. 
 
 In a study conducted in INDIA by BHATTACHARYA et al on 62 
individuals bitten by  suspected rabid animals using purified vero cell 
vaccine, 4 doses of vaccines were given on day 0, 3, 7 and 14. They all 
develop adequate antibodies after 4 doses. In contrast, our study result 
showed that even after 3rd dose adequate antibody levels were reached. 
 
 in a study conducted in USA by JONES RL et al on 680 adult healthy 
volunteers using either human diploid cell vaccine or 
chromatographically purified rabies vaccine along with 
immunoglobulin, the vaccines were given as 5 doses on day 0, 3, 7, 14 
and 28. All develop adequate antibodies on day 14. This correlates 
with our study result. But there was no comparison with the fourth 
dose. 
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  In a study conducted in WISCONSIN by LANG J et al on 32 adult 
healthy volunteers using either human diploid cell vaccine along with 
immunoglobulin, the vaccines were given as 5 doses on day 0, 3, 7, 14 
and 28. All develop adequate antibodies on day 14. This correlates 
with our study result. But there was no comparison with the fourth 
dose. 
 
  In a study conducted in THAILAND by BRIGGS DJ et al on 57 
individuals presenting for post exposure prophylaxis using purified 
chick embryo cell vaccine with or without immunoglobulin depending 
upon the wound class, the vaccine were given as 6 doses on day 0, 3, 7, 
14, 28 and 90. They all develop adequate antibody levels after 4 doses. 
In contrast, our study result showed that even after 3rd dose adequate 
antibody levels were reached. 
 
 In our study the rise in antibody titer when comparing the third 
dose with fourth dose is highly significant. Therefore fourth dose 
of anti-rabies vaccination should be given. 
 
 In a knowledge, attitude and practice study conducted in SRILANKA 
by GINO C MATIBAG et al regarding rabies found that knowledge 
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was adequate but attitude and health practice should be improves. This 
correlates with our study result. 
 
 In our study of knowledge attitude and practice regarding dog 
bite, knowledge was adequate but the attitude and practice were 
inadequate and should be improved. 
 
 
 
  
  
 
 
 
CONCLUSION 
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CONCLUSION 
 
1. In our study the rise in antibody titer when comparing the third dose 
with fourth dose is highly significant. Therefore fourth dose of anti-
rabies vaccination should be given. 
 
2. In our study of knowledge attitude and practice regarding dog bite, 
knowledge was adequate but the attitude and practice were 
inadequate and should be improved. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
LIMITATIONS 
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LIMITATIONS 
 
 One limitation of this study is low number of patients. The results 
should be confirmed in study involving large number of patients. 
 
 Long term follow up is required to assess the longevity of the anti-
rabies antibody levels. 
 
 Study should include the other approved anti-rabies vaccines for 
intramuscular route in assessing the antibody response. 
  
 
 
 
BIBLIOGRAPHY 
  
BIBLIOGRAPHY 
 
1. Evidence for a 4-dose vaccine schedule for human rabies post-
exposure prophylaxis in previously non-vaccinated individuals. 
Vaccine. 2009 Nov 27; 27(51):7141-8. doi: 10.1016/ 
j.vaccine.2009.09.029 
 
2. Baer GM.  Rabies:  An historical perspective. Infect  Agents  Dis. 
1994;3:168-180 
 
3. Wunner WH.  The  chemical  composition  and  molecular     
Structure of rabies viruses.  In:  Baer GM, Ed. The Natural     
History of Rabies.  2nd Ed.  Boca Raton, Fla:  CRC Press; 1991: 
    31-67. 
 
4. Sokol F, Schlumberger HD, Wiktor TK, et al. Biochemical and 
biophysical  studies  on  the  nucleocapsid  and  on  the  RNA  of 
Rabies virus. Virology. 1969; 38:651-665. 
 
5. Dietzschold B, Rupprecht CE, Fu ZF, et al.  Rhabdoviruses.  In: 
Fields BN, Knipe DM, Howley PM, et al, eds. Fields Virology. 3rd 
ed. Philadelphia: Lippincott Raven; 1996:1137-1159. 
 6. Tordo N, Poch O, Ermine A, et al.  Walking  along  the  rabies 
Genome: Is the large G-L intergenic region a remnant gene? Proc 
Natl Acad Sci U S A. 1986; 83:3914-3918. 
 
7. Bleck TP, Rupprecht CE.  Rhabdoviruses.  In:  Richman DD,  
Whitley RJ, Hayden FG, eds. Clinical Virology.  2nd Ed.  
Washington, DC: ASM Press; 2002:857-873. 
 
8. Yang J, Koprowski H, Dietzschold B, et al. Phosphorylation of  
Rabies virus nucleoprotein regulates viral RNA transcription and  
Replication by modulating leader RNA encapsidation. J  Virol.  
1999; 73:1661-1664. 
 
9.  Wu X, Gong X, Foley HD, et al.  Both viral transcription and  
Replication are reduced when the rabies virus nucleoprotein is Not 
phosphorylated. J Virol. 2002; 76:4153-4161. 
 
10.  Goto H, Minimoto N, Ito H, et al. Expression of the nucleoprotein  
of rabies virus in Escherichia coliand mapping of antigenic Sites. 
Arch Virol. 1995; 140:1061-1074. 
 
11.  Blumberg BM, Giorgi C, Kolakofsky D. N protein of vesicular  
 Stomatitis virus selectively encapsidates leader RNA in vitro.  
Cell. 1983; 32:559-567. 
 
12.  Tordo N, Poch O, Ermine A, et al. Completion of the rabies virus  
Genome sequence determination:  Highly conserved domains 
Among the L (polymerase) proteins of unsegmentednegativestrand 
RNA viruses. Virology. 1988; 165:565-576. 
 
13.  Levy JA, Fraenkel-Conrat H, Owens RA. Virology.  Englewood  
       Cliffs, NJ: Prentice Hall; 1994:77-85. 
 
14.  Coll JM.  The glycoprotein G of rhabdoviruses.  Arch Virol.  
        1995; 140:827-851. 
 
15.  Mebatsion T, Weiland F, Conzelmann KK.  Matrix protein of  
rabies  virus  is  responsible  for  the  assembly  and  budding  of 
Bullet-shaped particles and interacts with the transmembrane 
Spike glycoprotein G. J Virol. 1999; 73:242-250. 
 
 
 
16.  Finke S, Mueller-Waldeck R, Conzelmann KK.  Rabies virus  
 Matrix protein regulates the balance of virus transcription and  
Replication. J Gen Virol. 2003; 84:1613-1621. 
 
17.  Finke S, Conzelmann KK.  Dissociation of rabies virus matrix  
Protein functions in regulation of viral RNA synthesis and virus 
Assembly. J Virol. 2003; 77:12074-12082. 
 
18.  Rupprecht CE, Dietzschold B, Wunner WH, et al. Antigenic    
        relationships of lyssaviruses. In: Baer GM, Ed. The Natural  
       History Of Rabies. 2nd ed. Boca Raton, Fla: CRC Press; 1991:69- 
       100. 
 
19.  Seif I, Coulon P, Rollin PE, et al.  Rabies virulence:  Effect on 
pathogenicity and sequence characterization of rabies virus 
Mutations affecting antigenic site III of the glycoprotein. J Virol. 
1985; 53:926-934. 
 
20.  Morimoto K, Ni Y-J, Kawai A. Syncytium formation is induced  
In the murine neuroblastoma cell cultures which produce 
Pathogenic G proteins of the rabies virus. Virology.  1992; 189: 
203-216. 
21.  Otvos L, Krivulka GR, Urge L, et al. Comparison of the effects Of  
amino acid substitutions and the β-N- vs. α-O-glycosylation On 
the T-cell stimulatory activity and conformation of an Epitope on 
the rabies virus glycoprotein. Biochim Biophys Acta. 1995; 
1267:55-64. 
 
22. Adapted from Rupprecht CE, Smith JS, Fekadu M, Childs JE. The  
ascension of wildlife rabies: A cause for public health concern or 
intervention? Emerg Infect Dis. 1995; 1:107-114. 
 
23. Jackson AC. Human disease. In: Jackson AC, Wunner AH, eds.  
      Rabies, 2nd edn. London: Elsevier, Academic Press; 2007:309–40. 
 
24.  Helmick CG, Tauxe RV, Vernon AA. Is there a risk to contacts of  
       patient’s withrabies? Rev Infect Dis 1987; 9:511–18 
 
25. Finke S, Conzelmann KK.  Dissociation of rabies virus matrix  
      Protein functions in regulation of viral RNA synthesis and virus      
      Assembly. J Virol. 2003; 77:12074-12082 
 
 
 
26. Murphy FA, Bauer SP, Harrison AK, et al. Comparative  
pathogenesis of rabies and rabies-like viruses:  Virus infection and 
transit from inoculation site to the central nervous system. Lab 
Invest. 1973; 28:361-376. 
 
27.  Watson HD, Tignor GH, Smith AL.  Entry of rabies virus into  
       The peripheral nerves of mice. J Gen Virol. 1981; 56:371-382. 
 
28.  Lentz TL, Barrage TG, Smith AL, et al. Is the acetylcholine  
       receptor a rabies virus receptor? Science. 1982; 215:182-184. 
 
29.  Lentz TL, Wilson PT, Hawrot E, et al.  Amino acid sequence  
Similarity between rabies virus glycoprotein and snake venom 
Curare mimetic neurotoxins. Science. 1984; 226:847-848. 
 
30.  Kelly RM, Strick PL. Rabies as a transneuronal tracer of circuits  
       In the central nervous system. J  Neurosci Methods.  2000; 103: 
                 63-71 
 
31. Esiri MM, Kennedy PGE. Virus diseases. In: Adams JH, Duchen  
      LW, eds. Greenfield’s Neuropathology.  New York:  Oxford  
      University Press; 1992:335-399 
32. De Brito T, Araujo MD, Tiriba A.  Ultrastructure of the Negri  
      Body in human rabies. J Neurol Sci. 1973; 20:363-372. 
 
33. Fishbein DB, Bernard KW.  Rabies virus.  In:  Mandell GM,  
      Bennett JE, Dolin R, eds. Principles and Practice of Infectious  
      Diseases. New York: Churchill Livingstone; 1994:1527-1543. 
 
34.  Hemachuda T, Phanthumchinda K, Phanuphak P, et al.   
       Myoedema as a clinical sign in paralytic rabies. Lancet. 1987;  
       1:1210. 
 
35. Gowers WR. A manual of diseases of the nervous system.  
      Philadelphia: Blakiston; 1888:1237-1254. 
 
36.  Warrell DA, Davidson NM, Pope HM, et al.  Pathophysiologic  
       Studies in human rabies. Am J Med. 1976; 60:180-190? 
 
37.  Cheetham HD, Hart J, Coghill NF, et al. Rabies with myocarditis:  
       Two cases in England. Lancet. 1970; 1:921-922 
 
 
 
38. Blenden DC, Creech W, Torres-Anjel MJ. Use of  
     immune fluorescence examination to detect rabies virus in the skin  
     of  Humans with clinical encephalitis. J  Infect Dis.  1986; 154: 
     698-701. 
 
39.  Crepin P, Audry L, Rotivel Y, et al. Intravital diagnosis of human  
       Rabies by PCR using saliva and cerebrospinal fluid. J Clan  
       Microbiol. 1998; 36:1117-1121. 
 
40.  Arai YT, Yamada K, Kameoka Y, et al. Nucleoprotein gene  
       analysis of fixed and street rabies virus variants using RT-PCR.  
       Arch Virol. 1997; 142:1787-1796. 
 
41.  Nadin-Davis SA. Polymerase chain reaction protocols for  
        rabiesvirus discrimination. J Virol Methods. 1998; 75:1-8 
 
42. Whitby JE, Johnstone P, Sillero-Zubiri C.  Rabies virus in the  
       Decomposed brain of an Ethiopian wolf detected by nested  
       Reverse transcription-polymerase chain reaction. J  Wildl Dis.  
       1997; 33:912-915. 
 
 
43.  Albas A, Ferrari CI, da Silva LH, et al. Influence of canine brain  
       Decomposition on laboratory diagnosis of rabies. Rev Soc Bras  
       Med Trop. 1999; 32:19-22. 
 
44.  Zaidman GW, Billingsley A.  Corneal impression test for the  
       Diagnosis of acute rabies encephalitis. Ophthalmology. 1998; 105: 
       249-251. 
 
45. Smith JS, Yager PA, Baer GM. A rapid reproducible test for    
      determining rabies neutralizing antibody.  Bull WHO.  
      1973; 48:535-541. 
 
46.  Alvarez L, Fajardo R, Lopez E, et al. Partial recovery from rabies  
       in a nine-year-old boy. Ped Infect Dis J. 1994;13:1154-1155. 
 
47.  Laothamatas J, Hemachuda T, Mitrabhakdi E, et al. MR imaging  
       In human rabies.  AJNR Am J Neuroradiology.  2003; 24:1102- 
       1109 
 
48. National Guidelines on Rabies Prophylaxis 2013 
 
 
49. Warrell MJ.  Current rabies vaccines and prophylaxis schedules:   
      preventing rabies before and after exposure.  Travel Med INF Dis    
      2012 (in press)doi:10.1016/j.tmaid.2011.12.005. 
 
50. Wiktor TJ, Doherty PC, Koprowski H.  In  vitro  evidence  of  cell- 
      mediated immunity  after  exposure  of  mice  to  both  live  and   
      inactivated  rabies  virus. Proceedings of the National Academy of  
      Sciences of the United States of America, 1977, 74:334–338. 
 
51.  Hooper C et al.  Collaboration  of  antibody  and  inflammation  in   
       clearance of  rabies  virus  from  the  central  nervous  system.     
       Journal of Virology, 1998, 72:3711–3719. 
 
52.  Moore SM et al. Detection of cellular immunity to rabies antigens  
        in human vaccines. Journal of Clinical Immunology, 2006,  
        26:533–545. 
 
53.  Brinkman DM et al.  Vaccination with rabies to study the humoral  
       and cellular immune response to a T-cell dependent neoantigen in  
       man. Journal of Clinical Immunology, 2003, 23:528–538. 
 
 
54 .Shankar V, Dietzschold B, Koprowski H. Direct entry of rabies  
      virus into the central nervous system without prior local   
      replication. Journal of Virology, 1991, 65:2736–2738. 
 
55.  Herzog M et al. Nucleocapsid specific T and B cell responses in  
       humans after rabies vaccination. Virus Research, 1992, 24:77–89. 
 
56. WHO position paper on rabies vaccines? Weekly Epidemiological  
      Record, 2010, 85 (31):293–308. 
 
57. WHO Expert Consultation on Rabies.  First Report. Ge n e v a,  
      World Health Organization, 2004 (WHO Technical Report Series,   
      No. 931). 
 
58.Rabies. Scientific Basis of the Disease and Its Management (2013)  
     Alan C.Jackson 
 
59. Clin Infect Dis. (2003) 36 (1): 60-63.doi: 10.1086/344905 
      http://cid.oxfordjournals.org/content/36/1/60.full 
  
 
 
 
ANNEXURES 
PROFORMA 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
 
CONTACT NUMBER  : 
COMPLAINTS   : 
 
 
PAST HISTORY   : 
 
 
TREATMENT HISTORY : 
 
DRUG ALLERGY  : 
GENERAL EXAMINATION : 
 
 
VITALS     : 
LOCAL EAMINATION OF BITE SITE: 
 
SYSTEMIC EXAMINATION 
 
CENTRAL NERVOUS SYSTEM: 
 
CARDIOVASCULAR SYSTEM: 
 
RESPIRATORY SYSTEM   : 
 
ABDOMEN           : 
 
 
DATE OF FIRST DOSE OF ARV: 
 
SERUM ANTI RABIES ANTIBODY TITERS 
ON 14TH DAY AFTER FIRST DOSE OF ARV [7 DAYS AFTER 3RD 
DOSE]   :  
ON 21ST DAY AFTER FIRST DOSE OF ARV [7 DAYS AFTER 4TH 
DOSE]   : 
COMPLIANCE  : 
KNOWLEDGE ATTITUDE AND PRACTICES REGARDING DOG 
BITE IN PATIENTS COMING FOR POST EXPOSURE 
PROPHYLAXIS 
 
1. What treatment options are available for dog bite? 
 
2. What is mode of transmission of rabies? 
 
3. How many days one should observe the dog following bite? And what 
for? 
 
4. Your opinion regarding wound washing and immediate wound 
suturing? 
 
5. Chances of survival if rabies develops? 
 
6. Your opinion regarding prophylaxis for provoked dog bite? 
 
7. Whether all doses of ARV In the schedule should be completed? 
 
8. Your opinion whether ARV needed in vaccinated dog bites? 
 
  
9. Whether avoidance of certain foods needed after dog bite for any 
particular period? 
 
10. Will rabies spread from human to human? 
 
  
   
 
  
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
  
  
INFORMATION SHEET 
We are conducting a study on “COMPARISON OF ANTIBODY TITERS BETWEEN 
THIRD AND FOURTH IM [INTRAMUSCULAR] DOSE OF ANTI RABIES 
VACCINATION FOLLOWING POST EXPOSURE PROPHYLAXIS WITH ANTI-
RABIES IMMUNOGLOBULIN, AND KAP [KNOWLEDGE ATTITUTE AND 
PRACTICE] AMONG PATIENTS COMING FOR POST EXPOSURE 
PROPHYLAXIS OF DOG BITE” among patients attending Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to us. 
 
The purpose of this study is to assess the “COMPARISON OF ANTIBODY TITERS 
BETWEEN THIRD AND FOURTH IM [INTRAMUSCULAR] DOSE OF ANTI 
RABIES VACCINATION FOLLOWING POST EXPOSURE PROPHYLAXIS WITH 
ANTI-RABIES IMMUNOGLOBULIN, AND KAP [KNOWLEDGE ATTITUTE AND 
PRACTICE] AMONG PATIENTS COMING FOR POST EXPOSURE 
PROPHYLAXIS OF DOG BITE” 
 
We are selecting certain cases and if you are found eligible, we may be using your 
specimen to perform extra tests and special studies which in any way do not affect your final 
report or management. 
 
The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of benefits to 
which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management or 
treatment. 
 
 
Signature of Investigator Signature of Participant 
PATIENT CONSENT FORM 
 
Study Title : “COMPARISON OF ANTIBODY TITERS BETWEEN THIRD AND 
FOURTH IM [INTRAMUSCULAR] DOSE OF ANTI RABIES 
VACCINATION FOLLOWING POST EXPOSURE PROPHYLAXIS 
WITH ANTI-RABIES IMMUNOGLOBULIN, AND KAP 
[KNOWLEDGE ATTITUTE AND PRACTICE] AMONG 
PATIENTS COMING FOR POST EXPOSURE PROPHYLAXIS OF 
DOG BITE” 
  
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
 
Name :  
 
Age/Sex :  
 
Identification Number :  
 
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in my own language 
 ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. 
 ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, even 
if I withdraw from the study I agree to this access. However, I understand that my identity will not 
be revealed in any information released to third parties or published, unless as required under the 
law. I agree not to restrict the use of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or unusual symptoms. 
 ❏ 
I hereby consent to participate in this study. 
 ❏ 
I hereby give permission to undergo complete clinical examination, diagnostic tests including 
hematological, biochemical tests and radiological tests. ❏ 
 
 
 
Signature/ Thumb impression                                     Signature of the investigator 
 
 
Patient’s name and address                                          Study Investigator’s name 
 
                                                                                    Dr. A.ABINANTHA RAJU 
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1 50 M 197.5 216.23 1 1 1 1 0 1 0 1 0 0 
2 44 M 150.26 180.25 1 1 1 1 0 1 0 1 0 0 
3 48 F 175.68 198.36 1 1 1 1 0 1 0 1 0 0 
4 45 M 181.47 199.65 1 1 1 1 0 1 0 1 0 0 
5 62 M 194.85 220.64 1 1 1 1 0 1 0 1 0 0 
6 16 M 184.89 193.63 1 1 1 1 0 1 1 1 1 0 
7 25 M 196.57 226.11 1 1 1 1 0 1 0 1 0 0 
8 65 M 176.24 193.26 1 1 1 1 0 1 0 1 0 0 
9 48 M 189.45 206.13 1 1 1 1 0 1 0 0 0 0 
10 35 M 166.74 195.2 1 1 1 1 0 1 1 0 1 0 
11 36 M 169.68 194.58 1 1 1 1 0 1 0 0 0 0 
12 66 M 173.25 206.03 1 1 1 1 0 1 0 0 0 0 
13 44 M 184.37 215.34 1 1 1 1 0 1 0 0 0 0 
14 52 M 210.55 220.35 1 1 1 1 0 1 0 1 0 0 
15 19 M 203.56 221.54 1 1 1 1 0 1 0 1 0 0 
16 54 M 184.36 199.33 1 1 1 1 0 1 0 1 0 0 
17 15 F 189.37 216.42 1 1 1 0 1 1 0 1 0 0 
18 36 F 178.35 204.03 1 1 1 1 0 1 1 1 1 0 
19 63 M 196.33 215.39 1 1 1 1 0 1 0 1 0 0 
20 44 F 183.2 213.06 1 1 1 1 0 1 1 1 1 0 
21 51 F 162.08 194.17 1 1 1 1 0 1 0 1 0 0 
22 62 F 178.26 201.25 1 1 1 1 0 1 1 1 1 0 
23 35 M 177.02 213.05 1 1 1 1 0 1 0 0 0 0 
24 26 M 189.05 210.32 1 1 1 1 0 1 1 0 1 0 
25 14 M 198.33 224.06 1 1 1 1 0 1 1 0 1 0 
26 56 M 186.06 214.36 1 1 1 1 0 1 1 0 1 0 
27 23 M 194.51 223.04 1 1 1 1 1 1 1 0 1 0 
28 26 M 162.89 183.02 1 1 1 1 0 1 1 1 1 0 
29 45 M 172.08 200.36 1 1 1 1 0 1 0 1 0 0 
30 65 M 163.24 189.49 1 1 1 0 0 1 0 1 0 0 
31 45 M 188.42 216.48 1 1 1 0 0 1 0 0 0 0 
32 63 M 163.24 198.55 1 1 1 1 0 1 1 0 1 0 
33 32 M 178.26 204.36 1 1 1 1 0 1 1 0 1 0 
34 39 M 184.33 214.77 1 1 1 1 0 1 1 0 1 0 
35 65 M 162.48 186.48 1 1 1 1 0 1 1 0 1 0 
36 24 M 172.22 194.89 1 1 1 0 0 1 1 1 1 0 
37 45 M 193.44 211.68 1 1 1 0 0 1 0 1 0 0 
38 36 M 186.48 198.14 1 1 1 0 0 1 0 1 0 0 
39 26 M 166.89 176.25 1 1 1 1 0 1 0 1 0 0 
40 32 M 156.33 186.79 1 1 1 1 0 1 0 1 0 0 
41 54 M 148.26 173.93 1 1 1 1 1 1 0 1 0 0 
42 55 F 163.78 177.58 1 1 1 1 1 1 0 1 0 0 
43 66 F 163.55 186.34 1 1 1 0 0 1 0 1 0 0 
44 62 F 153.26 199.06 1 1 1 1 0 1 0 1 0 0 
45 53 M 188.49 221.25 1 1 1 1 1 1 0 1 0 0 
46 43 M 146.78 194.27 1 1 1 1 0 1 0 1 0 0 
47 65 M 186.33 206.91 1 1 1 1 1 1 1 1 1 0 
48 15 M 168.29 189.04 1 1 1 1 0 1 0 1 0 0 
49 65 M 173.99 215.03 1 1 1 1 0 1 0 1 0 0 
50 45 F 186.47 206.46 1 1 1 1 0 1 0 0 0 0 
51 54 F 201.33 222.46 1 1 1 1 0 1 0 0 0 0 
52 49 M 196.35 216.21 1 1 1 1 0 1 0 0 0 0 
53 68 F 146.25 186.34 1 1 1 1 0 1 0 0 0 0 
54 47 F 169.77 179.03 1 1 1 1 0 1 0 0 0 0 
55 56 M 158.26 198.04 1 1 1 1 0 1 0 0 0 0 
56 36 M 154.39 173.29 1 1 1 1 0 1 1 0 1 0 
57 59 M 163.48 196.28 1 1 1 1 0 1 0 0 0 0 
58 62 M 148.33 183.26 1 1 1 1 0 1 0 1 0 0 
59 53 M 186.49 203.15 1 1 1 1 0 1 0 1 0 0 
60 59 M 166.03 198.35 1 1 1 1 0 1 0 1 0 0 
61 65 M 155.98 184.26 1 1 1 1 0 1 0 1 0 0 
62 59 M 184.26 207.65 1 1 1 1 0 1 0 1 0 0 
63 15 M 145.06 198.34 1 1 1 1 0 1 1 1 1 0 
64 26 M 213.05 218.35 1 1 1 1 0 1 0 0 0 0 
65 32 M 216.36 224.16 1 1 1 1 0 1 0 0 0 0 
66 58 F 186.24 201.49 1 1 1 1 0 1 0 0 0 0 
67 49 F 166.36 189.24 1 1 1 1 0 1 0 0 0 0 
68 65 F 189.63 196.78 1 1 1 1 0 1 0 0 0 0 
69 58 M 146.22 173.25 1 1 1 1 0 1 1 0 1 0 
70 56 F 169.04 196.27 1 1 1 1 1 1 0 0 0 0 
71 49 F 178.22 201.56 1 1 1 1 0 1 0 1 0 0 
72 43 F 156.08 178.33 1 1 1 1 1 1 0 1 0 0 
73 48 M 174.32 196.27 1 1 1 1 1 1 0 1 0 0 
74 15 M 186.06 201.56 1 1 1 1 0 1 1 1 1 0 
75 68 M 198.35 213.89 1 1 1 1 1 1 0 0 0 0 
76 43 F 163.28 198.24 1 1 1 1 0 1 0 0 0 0 
77 29 M 145.32 183.21 1 1 1 1 0 1 0 0 0 0 
78 65 F 198.26 221.45 1 1 1 1 0 1 0 0 0 0 
79 26 M 186.24 201.65 1 1 1 1 0 1 0 0 0 0 
80 30 F 174.36 203.81 1 1 1 1 0 1 1 0 1 0 
81 60 M 189.45 207.36 1 1 1 1 0 1 0 0 0 0 
82 19 M 189.32 204.21 1 1 1 1 1 1 0 0 0 0 
83 64 M 146.89 186.22 1 1 1 1 0 1 0 0 0 0 
84 28 F 166.24 194.26 1 1 1 1 0 1 1 0 1 0 
85 26 M 189.64 205.68 1 1 1 1 0 1 0 0 0 0 
86 39 M 198.65 226.35 1 1 1 1 0 1 0 1 0 0 
87 37 M 201.35 224.3 1 1 1 1 0 1 0 1 0 0 
88 15 M 176.54 189.23 1 1 1 1 0 1 0 1 0 0 
89 41 M 178.66 192.03 1 1 1 1 0 1 0 1 0 0 
90 26 F 186.47 196.43 1 1 1 1 0 1 0 1 0 0 
91 24 F 153.26 186.05 1 1 1 1 0 1 0 0 0 0 
92 53 F 148.33 197.02 1 1 1 1 0 1 0 0 0 0 
93 68 F 198.32 201.56 1 1 1 1 0 1 0 0 0 0 
94 53 M 168.24 196.24 1 1 1 1 0 1 0 0 0 0 
95 54 M 163.49 198.32 1 1 1 1 1 1 0 0 0 0 
96 24 M 165.23 175.03 1 1 1 1 1 1 0 0 0 0 
97 56 M 149.79 163.04 1 1 1 1 0 1 0 0 0 0 
98 24 M 168.94 193.06 1 1 1 1 0 1 0 0 0 0 
99 35 M 198.32 213.58 1 1 1 1 0 1 0 0 0 0 
100 41 M 186.24 221.38 1 1 1 1 0 1 0 0 0 0 
